. However, the precise role of the ligand in hormonal gene regulation is not well understood (3). Recently, evidence has accumulated that hormone receptors can be activated in the absence of their physiological ligands by second messenger signal transduction pathways, which probably influence receptor phosphorylation (4). Interestingly, both ligand-induced and ligand-independent receptor activation can be inhibited by hormone antagonists (5).
. However, the precise role of the ligand in hormonal gene regulation is not well understood (3) . Recently, evidence has accumulated that hormone receptors can be activated in the absence of their physiological ligands by second messenger signal transduction pathways, which probably influence receptor phosphorylation (4). Interestingly, both ligand-induced and ligand-independent receptor activation can be inhibited by hormone antagonists (5) .
Antiprogestins, like RU 486, have a great therapeutic potential in fertility control and treatment of hormonedependent tumors. They compete with natural ligands for binding to the progesterone receptor (PR), but why the complex of receptor and antiprogestins is functionally inactive is not clear (6) . It is known that antiprogestins influence the conformation of the receptor (7) (8) (9) (10) and may impair the dissociation of PR from heat shock proteins (11) . Prevalent models assume the existence of two types of antiprogestins (6) . Members of one class, represented by ZK 98299, are considered to be pure antagonists and to prevent binding of the receptor to DNA (12) . Other antiprogestins, such as RU 486, can be partial agonists and are supposed to enable DNA binding of the PR but to generate receptor complexes unable to activate hormone responsive genes (13, 14 extension with radioactive labeled primer. Sequences of the oligonucleotides are as follows: C-C3H, CCC TCT GAA AGG TGA AGG; A25, AGG ATA AGT GAC GAG CGG AGA CGG G; A, GAC GAG CGG AGA CGG GAT GGC GAA CAG.
Quantitation of Footprints. Quantitation of the genomic footprint experiment was performed with a Phosphorlmager (Molecular Dynamics) and GENEIMAGE 3.0 software. The band intensity was corrected for differences in loading by normalizing for the total radioactivity per lane. Correction for the intensity of bands that obviously did not change intensity in any of the methylation protection experiments led to identical results.
RESULTS
Correlation Between Agonist Induction and Protection over the MMTV Promoter. The effects of agonists and antagonists on transcriptional activity and binding of the PR to the MMTV promoter in vivo were tested. Induction of MMTV transcription was dependent on the concentration of the synthetic progestin agonist R 5020, with half-maximal effect observed in the nanomolar range (Fig. 1A) . Analysis of the transcription rate in nuclear runon experiments demonstrated that induction was detectable after 15 min and that near-maximal transcription rates were attained 30 min after addition of R 5020 (data not shown). Using DMS genomic footprinting, we found a dose-dependent protection of the guanines in all four TGTTCT motifs of the HREs 30 min after hormone stimulation (Fig. 1B, lanes 3-5) . As the protection pattern is very similar to that generated by PR binding to the MMTV promoter in vitro (19) , we assume that the protection is due to agonist-dependent occupancy of the HREs by the PR. Receptor binding is seen as early as 5 min after hormone addition and the sites remain occupied after 75 min (data not shown; see also Fig. 3) . Quantitation of the extent of protection shows a good correlation between PR binding and transactivation (Fig. 1A) , suggesting that bound PR molecules are required for promoter activation.
Simultaneously with the protection of the HREs we detect protection ofthe two guanine residues within the binding site for the transcription factor NF-I (Figs. 1B and 2 B and C), which is thought to be recruited to the promoter upon hormone stimulation (20, 21) . A weak protection is also found over the octamer motifs (Figs. 1B and 2 B and C), which are known to contribute only partially to hormone-dependent transcription of the MMTV promoter in these cell lines (22) . Atrins Do Not Generate Protection over the MMTV Promoter. Neither RU 486 nor ZK 98299 showed any agonistic activity in T47D-MTVL cells, while either antagonist at 1 mM completely inhibited induction by 10 nM R 5020 ( Fig.  2A) . Thus, in this assay both antiprogestins behave as pure antagonists. Furthermore, no PR binding to the HREs could be detected at high concentrations of RU 486 (Fig. 2B) . Similar results were obtained with ZK 98299 (Fig. 2C) . Therefore, under conditions where RU 486 and ZK 98299 behave as pure antagonists, they are not able to elicit significant binding of PR to the MMTV promoter in vivo.
Antiprogestins Inhibit Protection over the M V Promoter Generated by the Agonist-Receptor Complex. The inability of antiprogestins to promote PR binding to the HREs of the MMTV promoter prompted us to investigate whether they are able to displace prebound agonist-PR complexes from DNA. In cells preincubated with R 5020, addition of RU 486 led to a rapid disappearance of PR footprints on the MMTV promoter, with half-maximal effect seen after 30 min (Fig. 3) . We therefore conclude that antiprogestins interfere with steps in the process of PR action that are needed for specific DNA binding and/or maintenance of PR-DNA complexes. Simultaneously with the disappearance ofthe PR footprint, antiprogestins also eliminate the footprint over the NF-I binding site and the weak protection over the octamer motifs (Fig. 3) (16) . As a control, ethanol was added to cells treated for 15 min with R 5020, and incubation was continued for an additional 60 min (R 5020 75'). studies, because they contain high levels of PR (12, (23) (24) (25) (26) . None of these experiments has provided evidence for proteins other than the receptor that might have the potential to bind to the four HREs of the MMTV promoter. This is important because of previous controversies concerning the nature of the protein protecting one of the HREs of the rat tyrosine aminotransferase gene in hepatocytes (27) . We therefore think that our T47D-MTVL cell line is particularly suitable to study hormone or antihormone effects on PR binding to the MMTV promoter in vivo. The good correlation between induction by the synthetic progestins R 5020 and protection against DMS methylation over the corresponding guanine residues of the HREs and the similarity to the methylation protection pattern observed with purified PR (19) The apparent contradiction between these findings and the lack of antiprogestin-induced PR binding according to in vivo footprinting could have multiple reasons related to the changes in receptor conformation. It is known that agonists and antagonists induce different conformations of the C-terminal region of the PR, as demonstrated by band shift assays, protease digestion, or antibody binding (7, 9) . While in vivo the active PR conformation is generated by binding of agonist ligands, in vitro conditions can induce this conformation even in the absence of ligand or in the presence of antihormones (23, 28, 29, 31) . In fact, deletion of the last 42 amino acids (9) , and even a single amino acid exchange (32) 
